Company intelligence / Profile preview
CoRegen
Houston, Texas, United Statescoregeninc.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CoRegen has raised over $93M to support CMC development and initiation of a Phase 1/2 trial for its SRC3-KO program, with a focus on solid tumors. The company is leveraging a platform that controls multiple genes and targets SRC-3 in regulatory T cells, aiming to enable immune eradication of cancer with reduced toxicity. Clinical results are pending as studies are in early stages.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on CoRegen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoRegen.